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Introduction: Topical administration of eye drops is the major route for drug delivery to the cornea. Orbital fat-
derived stem cells (OFSCs) possess an in vitro corneal epithelial differentiation capacity. Both the safety and
immunomodulatory ability of systemic OFSC transplantation were demonstrated in our previous work. In this study,
we investigated the safety, therapeutic effect, and mechanism(s) of topical OFSC administration in an extensive
alkali-induced corneal wound.
Methods: Corneal injury was created by contact of a piece of 0.5 N NaOH-containing filter paper on the corneal
surface of a male Balb/c mouse for 30 s. The area of the filter paper covered the central 70% or 100% of the
corneal surface. OFSCs (2 × 105) in 5 μl phosphate-buffered saline (PBS) were given by topical administration (T)
twice a day or by two intralimbal (IL) injections in the right cornea, while 5 μl of PBS in the left cornea served as
the control.
Results: Topical OFSCs promoted corneal re-epithelialization of both the limbal-sparing and limbal-involved corneal
wounds. In the first three days, topical OFSCs significantly reduced alkali-induced corneal edema and stromal
infiltration according to a histopathological examination. Immunohistochemistry and immunofluorescence staining
revealed that transplanted cells were easily detectable in the corneal epithelium, limbal epithelium and stroma, but
only some of transplanted cells at the limbal epithelium had differentiated into cytokeratin 3-expressing cells. OFSCs
did not alter neutrophil (Ly6G) levels in the cornea, but significantly reduced macrophage (CD68) infiltration and
inducible nitrous oxide synthetase (iNOS) production during acute corneal injury as quantified by a Western blot
analysis. Continuous topical administration of OFSCs for seven days improved corneal transparency, and this was
accompanied by diffuse stromal engraftment of transplanted cells and differentiation into p63-expressing cells at
the limbal area. The therapeutic effect of the topical administration of OFSCs was superior to that of the IL
injection. OFSCs from the IL injection clustered in the limbal area and central corneal epithelium, which was
associated with a persistent corneal haze.
Conclusions: Topical OFSC administration is a simple, non-surgical route for stem cell delivery to promote corneal
tissue regeneration through ameliorating acute inflammation and corneal epithelial differentiation. The limbal area
serves as a niche for OFSCs differentiating into corneal epithelial cells in the first week, while the stroma is a
potential site for anti-inflammation of OFSCs. Inhibition of corneal inflammation is related to corneal transparency.
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Both a limbal cell deficiency and corneal stromal injury
affect long-term corneal transparency due to corneal
opacity [1]. During corneal tissue injury, inflammation is
harmful to epithelial cell migration, and inflammatory
cell infiltration in the stroma aggravates corneal edema
and scarring [2]. The cornea is physiologically re-
epithelialized by the proliferation and differentiation of
limbal stem cells in the basal layer of the limbal epithe-
lium [3,4], and extensive loss of limbal epithelial cells
leads to a persistent corneal epithelial defect and pannus
formation [5]. Damage to the corneal stroma represents
corneal ulceration, and this is complicated by corneal
opacity due to scar formation [6].
Corneal transplantation is a way to replace scar tissue
using the full or partial thickness of a donor’s central
cornea [7], but it fails to regenerate limbal stem cells.
Moreover, the donor source and graft rejection are
major limitations of corneal transplantations [8]. Limbal
transplantation is a surgical procedure that removes au-
tologous limbal epithelium from the contralateral eye to
replenish diseased limbal epithelium [9]; disruption of
healthy limbal stem cells is inevitable. Recently, replace-
ment of the corneal epithelium under a limbal cell defi-
ciency is achieved by ex vivo cultured cells, including
limbal stem cells [10,11], conjunctival epithelial cells
[12], and oral mucosal cells [13]. However, long-term
graft survival is always a challenge with autologous con-
junctival or oral epithelial cell transplantation due to a
lack of stem cell properties of those cells. Stem cell
transplantation is a new therapeutic strategy for corneal
tissue regeneration that relies on their multipotency.
In terms of stem cell therapy, healthy limbal stem cell
preservation and immune tolerance of stem cells are two
critical issues for successful corneal regeneration [14,15],
and it is imperative to use immune-tolerant allogenic
stem cells. Among stem cells, only mesenchymal stem
cells (MSCs) possess the immunomodulatory ability and
are well-tolerated during allogenic transplantation [16].
We have successfully isolated and purified multipotent
stem cells from human orbital fatty tissues [17]. Orbital
fat-derived stem cells (OFSCs) are MSCs isolated from
human orbital fat tissue [18]. In our previous study, we
have demonstrated that the growth kinetics of OFSCs is
similar to bone marrow-derived MSCs (BM-MSCs),
while more than 260 surface markers of OFSCs are
consistent with BM-MSCs [17,19,20]. OFSCs lack
immunogenecity, and the safety and immunomodula-
tory ability of systemic OFSC transplantation has been
demonstrated in our previous xenotransplant model
[20]. In addition, OFSCs possess the osteogenic,
chondrogenic and adipogenic differentiation capacity,
and may differentiate into corneal epithelial cells upon
contact with human corneal epithelial cells in vitro [17].Therefore, development of a technically non-surgical,
non-invasive method to deliver OFSCs and allow OFSCs
to directly contact corneal epithelial cells will be valuable
for corneal tissue regeneration.
In this study, extensive corneal injury was created by
NaOH, an alkali chemical reagent. Alkali-induced cor-
neal injury leads to corneal/limbal epithelial defects, and
induces further stromal tissue melting and severe cor-
neal inflammation, which subsequently results in corneal
edema, ulceration in the early stage, and corneal opa-
city/scarring in the late stage [21]. We created two sizes
of corneal wounds, that is, one was a limbal-sparing
central corneal injury and the other was total corneal
damage, including the limbal area. OFSCs were topic-
ally administrated to the corneal surface, and the thera-
peutic effect was evaluated by the size of the corneal
defect, the corneal thickness, stromal infiltration and
corneal transparency. In this experiment, the mechan-
ism and the niche of OFSCs before and after corneal
re-epithelialization were explored. In addition, differ-
ences in limbal-involved corneal injury between topical
OFSCs and an intralimbal injection of OFSCs were also
compared.
Material and methods
Animals with the corneal injury
Male Balb/c mice were purchased from BioLASCO
(Taipei, Taiwan). Animals were maintained in the animal
facility of Wan Fang Hospital, Taipei Medical University
(WFH-TMU, Taipei, Taiwan). All experimental protocols
were approved by the animal use and care committee of
WFH-TMU. An eight-week-old mouse’s cornea was cov-
ered by round filter paper, which had been rinsed by 0.5
N NaOH before covering the mouse corneal surface for
30 s. Mice were separated into two groups: filter paper
in group A covered 70% of the central corneal area
(5.9 mm in diameter) and in group B, filter paper cov-
ered 100% of the corneal area (7 mm in diameter).
Corneal epithelial cells were smoothly removed with a
no. 15 Bard-Parker scalpel blade after alkali damage.
Isolation, expansion of OFSCs
Isolation and culture of OFSCs were carried out as de-
scribed previously [17]. Briefly, during blepharoplastic
surgery, 0.5 to approximately 1 ml of redundant orbital
fat tissues was removed from the intraorbital cavity. All
samples were removed with informed consent and
followed regulations of the Institutional Review Board of
WFH-TMU. Tissues were fragmented, digested and fil-
tered. The suspension was centrifuged, cells from the
pellet were plated at a very low density, and colony-
forming cells were maintained in MesenPro medium
(Invitrogen, Carlsbad, CA, USA). OFSCs were mesen-
chymal stem cells which were negative for CD34,
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HLA-DR and positive for CD58, CD90, CD105, CD29,
CD49b, CD49e, CD44, CD49d and HLA-ABC [17]. The
tri-lineage differentiation capacity of these cells was
checked before this study.
Topical and intra-limbal OFSC transplantation
Six mice were used in Group A. After 70% of corneal in-
jury to both eyes, the right eye was applied with topical
OFSCs (T) and the left eye with PBS. Night mice were
used in Group B for the topical (T) administration of
OFSCs. After 100% of corneal injury for both eyes took
place, topical OFSCs were given to the right eyes while
topical PBS (six mice) or no treatment (dry control,
three mice) to the left eyes. In addition, three mice with-
out corneal injury received topical OFSCs on the right
eyes and topical PBS on the left eyes.
For evaluation of the intra-limbal (IL) injection, 100%
corneal injury was created on three mouse corneas. IL
injection of OFSCs was performed in the right eye and
PBS in the left eye. One mouse without corneal injury
received IL OFSCs in the right eye and IL PBS in the left
eye.
Before treatment, OFSCs were detached and re-
suspended in PBS(Gibco, Grand Island, NY, USA). For
topical (T) administration, 2 × 105 human OFSCs with
or without quantum dots (Invitrogen) labeling in 5 μl of
PBS were applied to the right corneal surface twice a day
until the day of sacrifice, while 5 μl of PBS applied to
the left eye twice a day served as the control. For the IL
injection, 2 × 105 quantum dots (Invitrogen)-labeled
OFSCs in 5 μl of PBS were injected into the lateral side
of the right limbal epithelium on the first day, and a re-
peat injection on the nasal side of the right limbal epi-
thelium was given on Day 6, while 5 μl of PBS was
injected into the left limbal epithelium at the same time.
Quantification the area of corneal injury
The cornea wound was examined on days 0, 1, 2, 3 and
7. Before being photographed, the epithelial defect was
stained with a topical fluorescent strip (HAAG-STREIT,
Koeniz, Switzerland), and images were captured with a
digital camera (Canon, Tokyo, Japan) under a cobalt-
blue light source from a direct ophthalmoscope (Welch
Allyn, Skaneateles Falls, NY, USA). The injured area of
the cornea was determined using the software Image
Pro-Plus version 6.0 (Media Cybernetics, Rockville, MD,
USA) and calculated as a percentage of the residual epi-
thelial defect.
Histological and immunohistochemical (IHC) staining
Mice were sacrificed at the end of day 2, 3 or 7 after in-
jury. The eyeball was removed en bloc and fixed in for-
malin, then prepared in paraffin-embedded blocks forsectioning at a thickness of 10 μm. Tissue sections were
stained with hematoxylin and eosin (H&E) (Sigma-
Aldrich, St. Louis, MO, USA). For IHC staining, tissue
sections were incubated with rabbit antibody against
human immunoglobulin G (hIgG) (1:800, Abcam,
Cambridge, MA, USA), or rabbit antibody against hu-
man beta-2 microglobulin (hβ2M) (1:800, Abcam) at 4°C
for 1 h, followed by goat antibodies against rabbit IgG
(Dako Cytomation, Glostrup, Denmark) for another 40 to
approximately 60 minutes. Tissue sections were assessed
by microscopy (Leica Microsystem, Wetzlar, Germany).
Images were acquired with MetaMorph version 4.6
(Molecular Devices, Sunnyvale, CA, USA).
Immunofluorescence staining
For cytokeratin 19 (CK19) and CK3 staining, frozen sec-
tion tissue slides were fixed in cold methanol for 30 mi-
nutes, followed by two PBS washes. After being blocked
in 5% skim milk at room temperature for 1 h, slides
were incubated with a mouse antibody against human/
mouse CK19 (1:500, Millipore, Billerica, MA, USA), a
mouse antibody against human/mouse CK3 (1:500,
Millipore), rabbit antibody against human p63 (1:150,
Abcam), or rabbit antibody against hIgG (1:800, Abcam)
at room temperature for 1 h, followed by incubation
with DyLight 488-conjugated goat anti-mouse IgG
(1:500, Jackson ImmunoResearch Laboratories, Inc.
West Grove, PA, USA), or DyLight 594-conjugated goat
anti-rabbit IgG (1:500, Jackson ImmunoResearch
Laboratories, Inc.) at room temperature for 30 minutes.
Nuclei were then stained with 4,6-diamidino-2-
phenylindole (DAPI, 1:1,000), and samples were assessed
under a fluorescence microscope (Leica Microsystem).
Images were acquired using MetaMorph version 4.6
(Molecular Devices).
Western blot analysis
Total protein was obtained from mouse cornea with Cell
Lysis Buffer (Sigma-Aldrich) containing freshly added
protease inhibitors (Sigma-Aldrich). Protein concentra-
tions were determined with a Bio-Rad Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA). Electro-
phoresis was performed using 30 μg of total protein by
10% sodium dodecylsulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and transferred to polyvinylidenedifluoride
membranes (Millipore). Nonspecific binding was blocked by
5% skim milk in TBST buffer (50 mMTris–HCl, pH 7.4;
150 mMNaCl, and 0.1% Tween 20) at room temperature
for 1 h. The membrane was then probed with a rabbit poly-
clonal antibody (pAb) to inducible nitrous oxide synthetase
(iNOS, 1:2000, Abcam), a rabbit monoclonal antibody
(mAb) to CD68 (1:1,000, Epitomics, Burlingame, CA, USA),
a rabbit pAb to tissue growth factor-beta (TGF-β, 1:4,000,
Abcam), a mouse mAb to tumor necrosis factor-alpha
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antigen 6 complex (Ly6G, 1:1,000, Abcam), a mouse
mAb to vascular endothelial growth factor (VEGF,
1:1,000, Abcam), a rabbit pAb to hIgG (1:800, Abcam),
a mouse mAb to mouse and human β-actin (1:200,
Sigma-Aldrich), or a mouse mAb to α-tubulin anti-
bodies (1:104, Sigma-Aldrich) at 4°C overnight. After
three washes with TBST (for 15 minutes each), the
membrane was incubated with a horseradish peroxidase
(HRP)-conjugated secondary antibody against to rabbit
IgG (1:5,000, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or against to mouse IgG (1:5,000, Abcam) at room
temperature for 1 h. After three more TBST washes, pro-
tein signals were detected by enhanced chemilumines-
cence (ECL; NEN Life Science, Boston, MA, USA) and
their intensities were measured by densitometry (Image
Pro-Plus version 6.0, Media Cybernetics).
Statistical analysis
Values are shown as the mean ± standard error. Statis-
tical analyses were performed using the StatisticalFigure 1 Orbital fat-derived stem cells (OFSCs) promoted corneal wou
Topical (T) administration of OFSCs promoted corneal wound healing (A) a
lower than that of the PBS group on Day 2 (B). In group B, a 100% corneal
significantly decreased with topical OFSC treatment. OFSCs promoted corn
with topical OFSCs after the second day (D). (t-test, * P <0.05).Package for Social Science version 16 software (SPSS,
Chicago, IL, USA). Results of comparisons of the area
of corneal injury at each time point between the PBS
and OFSCs groups or between the dry control and
OFSCs groups, and corneal protein expression between
the PBS and OFSCs groups were analyzed by Student’s
t-test, and P <0.05 was considered a statistically signifi-
cant difference.
Results
OFSCs promote corneal wound healing
Mice were divided into two groups. A 70% central cor-
neal injury (limbal-sparing) was created in group A, and
100% corneal damage (limbal-involved) was created in
group B. Topical 2 × 105 OFSCs in 5 μl PBS (OFSCs-
(T)) was administrated to the right corneal surface twice
a day, and topical 5 μl PBS (PBS-(T)) was given to the
left cornea twice a day.
For the limbal-sparing corneal wound (group A),
OFSCs promoted corneal re-epithelialization (Figure 1A).
Areas of the epithelial defect after alkali-injury werend healing. In group A, a 70% central corneal defect was created.
nd the area of residual epithelial defect under OFSCs was significantly
injury with limbal involvement was created. The injured area
eal re-epithelialization (C), and the injured area significantly decreased
Lin et al. Stem Cell Research & Therapy 2013, 4:72 Page 5 of 12
http://stemcellres.com/content/4/3/7271.3% ± 3.03% of the total cornea, 49.8% ± 6.87% on Day 1,
and 33.2% ± 10.06% on Day 2, while they were 71.2% ±
5.13% after injury, 40.8% ± 10.64% on Day 1, and 12.8% ±
6.77% on Day 2 with topical OFSC treatment (Figure 1B).
For limbal-involved corneal wounds (group B), OFSCs
accelerated corneal wound healing but a central corneal
haze was found in the first three days (Figure 1C). In
mice with a 100% corneal epithelial defect after alkali-
injury, areas of the epithelial defect under PBS treatment
were 74.8% ± 4.32% of the total cornea on Day 1,
59.6% ± 9.37% on Day 2, 42.0% ± 2.74% on Day 3, and
29.3% ± 6.78% on Day 7; while they were 64.2% ± 4.59%
on Day 1, 40.2% ± 3.06% on Day 2, 15.0% ± 7.83% on
Day 3, and 7.9% ± 2.34% on Day 7 with topical OFSC treat-
ment (Figure 1D). Compared with PBS control, the dry
control on a 100% corneal injury showed no significant dif-
ference on both corneal haze (Figure 1B, Dry-D3) and re-
sidual corneal defect (Figure 1D) in the first seven days.Figure 2 Topical OFSCs were initially engrafted into the corneal epith
cells, expressed human immunoglobulin (hIgG) and human β-2 microglobu
not found in the PBS-treated central cornea (B) and limbal area (C). In the
central epithelium (D), limbal epithelium (E) and stroma area (D, E).Topical OFSCs’ initial contact with the corneal epithelium,
limbal epithelium, and stroma
OFSCs, isolated from human orbital fat tissues, may be
distinguished from murine cells by targeting human-
specific housekeeper proteins, i.e. hIgG (Figure 2A, left)
and hβ2M (Figure 2A, right). To identify the distribution
of transplanted cells, hβ2M and hIgG were stained on cor-
neal sections. In PBS-treated eyes, no human cells were
detectable in either the central cornea (Figure 2B) or
limbal area (Figure 2C). In OFSC-treated eyes, hβ2M and
hIgG-expressing cells were found in the central corneal
epithelium (Figure 2D), limbal epithelium (Figure 2E) and
stroma (Figure 2D,E).
Initial corneal epithelial differentiation of OFSCs is
observed in the limbal epithelium
We further determined whether transplanted OFSCs dif-
ferentiated into corneal epithelial cells within three days.elium, limbal epithelium and stroma. OFSCs, different from murine
lin (hβ2M) (A). Two human-specific proteins, hβ2M and hIgG, were
limbal-involved corneal wound, topical OFSCs were detected in the
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the limbal cornea (Figure 3A, B) as a libal progenitor
marker [22,23], and no human cells expressing CK19 were
found (Figure 3B). Although OFSCs were found in the cor-
neal epithelium, limbal epithelium and stroma (Figure 2C,
D), no OFSCs differentiated into CK3-expressing cells,
which is a marker of a well-differentiated cornea, in the
central cornea (Figure 3E). Some transplanted cells co-
expressing CK3 were found in the limbal epithelium
(Figure 3F, yellow arrows).
OFSCs reduce alkali-induced acute inflammation and
corneal edema
During the first three days, severe inflammatory cell in-
filtration and increases in the corneal thickness wereFigure 3 Initial corneal epithelial differentiation of OFSCs was observ
stained in the limbal area, but neither human immunoglobulin G (hIgG) nor C
treatment of the limbal-damaged cornea for three days (B). CK3 expression w
after topical OFSC treatment, some hIgG and CK3 co-expressing cells were obfound in the stroma of the central cornea (Figure 4A,
brown arrow) and limbal area (Figure 4B, brown arrow);
this was (Figure 4A, left, 4B, left) or was not (Figure 4A,
right, 4B, right, blue arrow) independent of the epithelial
defect. OFSCs significantly ameliorated alkali-induced
stromal infiltration, and this was also independent of
corneal re-epithelialization (Figure 4C,D). In the area of
re-epithelialization (Figure 4C, right, 4D, right, blue
arrow), OFSCs further reduced the corneal thickness, es-
pecially in the central area (Figure 4C, right).
OFSCs inhibit macrophage infiltration and iNOS
production during acute corneal inflammation
Both macrophage and neutrophil infiltration occurred in
response to acute tissue injury. We performed a Westerned in the limbal epithelium. (A) Cytokeratin (CK) 19 was primarily
K19 co-expressing cells were found in the limbal area after topical OFSC
as noted in both the central (C, E) and limbal (D, F) cornea. Three days










H & E H & E
Central cornea-PBS (T)-D3 Central cornea-PBS (T)-D3 Limbus-PBS (T)-D3 Limbus-PBS (T)-D3
Central cornea-OFSCs(T)-D3 Central cornea-OFSCs(T)-D3 Limbus-OFSCs (T)-D3 Limbus-OFSCs (T)-D3
Figure 4 OFSCs reduced alkali-induced inflammation and corneal edema. An alkali reagent induced a large corneal epithelial defect with
severe stromal infiltration and corneal edema in the first three days, which were found in the central cornea (A) and limbal area (B). OFSCs
promoted corneal re-epithelialization, decreased stromal infiltration and reduced corneal thickness in the central cornea (C) and limbal area (D).
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of Ly6G, a neutrophil marker [24], and CD68, a macro-
phage marker [25], between PBS- and OFSC-treated
corneas three days after alkali injury. It was demon-
strated that OFSCs did not alter Ly6G protein expres-
sion (Figure 5A) but significantly decreased the CD68
level (Figure 5B). Furthermore, macrophage-produced
iNOS and several macrophage-released cytokines, such
as TGF-β, TNF-α and VEGF [26-29], were reported to
enhance corneal inflammation, neovascularization and
persistence of epithelial defects. We found that OFSCs
had no effect on TNF-α (Figure 5C), TGF-β (Figure 5D)
or VEGF (Figure 5F) protein expressions, but signifi-
cantly reduced iNOS production (Figure 5G).
Intra-limbal injection of OFSCs is not sufficient to clear
the cornea
The limbal area served as a place for corneal epithelial
cell differentiation (Figure 3F). We further sent quantum
dots-labeled OFSCs into the corneal area by intra-limbal
(IL) injection and avoided OFSCs contacting the corneal
stroma. As shown in Figure 6, repeated IL injection of
OFSCs in an intact cornea did not alter corneal trans-
parency (Figure 6A). However, neither hβ2M nor human
p63 expressing cells could be found at the injection site
(Figure 6B). The therapeutic effect of IL OFSC injection
in a damaged cornea with limbal involvement (Figure 6C)
was not compatible with topical OFSC administration
(Figure 7C) in the first seven days. We found that someOFSCs clustered at the injection site (Figure 6D), and
some were located in the central corneal epithelium
(Figure 6D, white arrow), but only a few of the injected
cells differentiated into p63, a human limbal progenitor
marker, positive cells.
Stromal engraftment of topical OFSCs contributes to
corneal transparency
Topical application of OFSCs in the first three days was
insufficient to improve corneal transparency in the
limbal-involved corneal wound (Figure 1C), so the long-
term effect of OFSCs needed to be investigated. For
safety consideration, multiple rounds of topical OFSCs
on the normal corneal surface did not attack the corneal
epithelium (Figure 7A). In the limbal-involved corneal
wound, a large corneal epithelial defect and marked cor-
neal opacity were observed under PBS treatment for
seven days (Figure 7B), and continuous topical OFSC ad-
ministration for seven days reduced the wound size and
improved the corneal transparency (Figure 7C). Fluores-
cent staining revealed that diffuse quantum dot-labeled
OFSCs were found in the corneal stroma, but no longer
in the central corneal epithelium (Figure 7D). Limbal
sections showed that some of the hβ2M-expressing cells
differentiated into p63 positive cells (Figure 7E).
Discussion
For the first time, we proved the concept that multiple
rounds of topical OFSCs is a simple, non-surgical
Figure 5 OFSCs inhibited macrophage infiltration and inducible nitric oxide synthase (iNOS) production in the cornea. A Western blot
analysis and its quantification demonstrated that OFSCs did not alter the expression of lymphocyte antigen 6 complex (Ly6G) (A) but significantly
decreased the CD68 (B) level in the cornea after alkali injury. Measurements of macrophage-related proinflammatory cytokine levels in the alkali-
damaged cornea revealed that OFSCs had no effect on regulating tumor necrosis factor (TNF)-α (C), transforming growth factor (TGF)-β (D), or
vascular endothelial growth factor (VEGF) (E), but significantly reduced iNOS (F). α-Tubulin served as the internal control. (t-test, * P <0.05).
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first three days, the therapeutic effects of topical OFSCs
are mainly through inflammation inhibition (Figures 1
and 4), but little by directional corneal epithelial cell dif-
ferentiation (Figure 3). Inhibition of macrophage infiltra-
tion and iNOS production (Figure 5) accounts for the
amelioration of acute corneal inflammation and promo-
tion of corneal re-epithelialization. OFSCs remain in the
limbal epithelium, corneal epithelium and stroma in the
first three days (Figure 2), and the limbal epithelium is
favored for corneal epithelial differentiation (Figures 3,
6E and 7E). However, the corneal stroma potentially
serves as a niche for OFSC engraftment, and this is re-
lated to improvements in the corneal transparency
(Figures 6 and 7).OFSCs, the same as BM-MSCs, lacked immunogen-
icity and were well-tolerated after intravenous injections
in our previous studies [20,30]. This time, we explored
whether topical administration (Figure 7A) and IL injec-
tions (Figure 6A) were safe routes to deliver MSCs into
corneal tissues. Clinically, the addition of topical steroids
or non-steroid anti-inflammatory drugs benefits corneal
re-epithelialization and prevents corneal scar formation
[31,32]. Systemic transplantation of a high dose of MSCs
reduce ethanol-induced inflammatory damage to the
cornea by secretion of TNF-α-stimulated gene/protein 6
with minimal engraftment [33], which shows that sys-
temic administration is not an efficient way to deliver
stem cells to the cornea, a physiologically avascular tis-
sue. However, the abundant paracrine effect of MSCs
Figure 6 Intra-limbal injection of OFSCs was not a proper route for corneal regeneration. For an intact cornea, repeated intra-limbal (IL)
injection of OFSCs was safe (A) but no p63-expressing cells were differentiated from transplanted cells (B). For an extensively damaged cornea,
corneal opacity was obvious after repeated IL OFSC injections (C). Quantum dot-labeled transplanted cells were clustered at the injection site,
and some were detectable in the central corneal epithelium (D). Only a few OFSCs differentiated into p63-expressing cells at the limbal area
seven days after corneal injury (E).
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reported that BM-MSCs expanded on an amniotic mem-
brane can reconstruct an alkali-damaged cornea by
inhibiting inflammation and angiogenesis [34]. Alterna-
tively, topical administration of stem cells provided stem
cells with direct contact with the corneal epithelium and
stroma on a damaged cornea (Figures 2 and 7D), and
low-dose OFSCs resulted in good corneal protection
(Figures 1, 3, 4 and 7).
Neutrophils and macrophages, known as immune
cells, are responsible for innate immunity, and infiltrate
into an acutely inflamed cornea [35]. Macrophages play
the central role in acute inflammation because they pro-
duce various proinflammatory cytokines, and also recruit
and activate T-lymphocytes [35,36]. Macrophage-produced
iNOS and VEGF cause a vicious cycle with alkali-induced
corneal inflammation [26,36]. According to our data,OFSCs inhibited macrophage infiltration and subsequent
iNOS production in the cornea (Figure 5B,F) without alter-
ing VEGF production (Figure 5E), indicating that macro-
phages are target cells regulated by OFSCs during acute
inflammation. Further studies on interactions between
OFSCs and macrophages in regulating acute tissue inflam-
mation are ongoing in our lab.
In our previous study, we found that cell-cell interac-
tions between corneal epithelial cells and stem cells were
crucial for corneal epithelial cell differentiation of OFSCs
[17]. When we applied OFSCs to the corneal surface
with a large epithelial defect, most of the transplanted
cells remained in the limbal epithelium, corneal epithe-
lium and stroma during the first few days (Figure 2).
Notably, only some of the OFSCs in the limbal epithe-
lium rapidly differentiated into CK3-expressing cells, but
no CK19 signals in transplanted cells were found in the
Figure 7 Diffuse stromal engraftment of OFSCs contributed to the corneal transparency. Seven days after multiple rounds of topical
administration (A), OFSCs had not harmed the cornea. For the limbal-involved corneal injury, topical OFSCs (C) showed better therapeutic effects
on wound healing and corneal transparency than topical PBS (B). Most quantum dot-labeled OFSCs were diffusely distributed in the stroma (D),
while some of transplanted cells differentiated into p63-expressing cells at limbal epithelium (E) seven days after topical OFSC administration.
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man p63-expressing cells were detectable at limbal area
seven days later (Figures 6E and 7E) rather than in the
first three days (data not shown), implying that the
limbal environment possibly induces OFSC differentiation
and transdifferentiation into a corneal epithelial linage.
The underlying mechanism should be determined.
Wound healing is essential for tissue regeneration.
However, the cornea is the window of the eye, and the
transparency of the cornea determines visual acuity.
Corneal tissues are physiologically composed of the cor-
neal epithelium, stroma and endothelium. Clarity of the
cornea depends on an intact corneal epithelium, tight
packing of epithelial cells, constant water content, and
regular arrangement of keratocytes and keratocyte-
produced extracellular matrix in the stroma [1,37,38]. In
this study, corneal opacity was not a complication of the
limbal-sparing corneal injury (Figure 1A). When OFSCs
were applied to the limbal-involved corneal wound,
marked central opacity was observed on Day 3 (Figure 1C),
and a clear cornea did not occur until Day 7 (Figure 7C),
suggesting that improved corneal clarity occurs after re-
epithelialization.We further delivered OFSCs into the limbal epithe-
lium of a damaged cornea to avoid OFSCs directly
contacting the corneal stroma. It was shown that cells
transplanted via an IL injection clustered at the injection
site and in the central corneal epithelium (Figure 6D),
and this was associated with marked corneal opacity
(Figure 6C, right). After seven days of continuous topical
OFSC administration, transplanted cells were only de-
tectable in the stroma and no longer in the corneal
epithelium (Figure 7D), illustrating that stromal en-
graftment of OFSCs contributes to corneal transpar-
ency. It has been reported that an intrastromal
injection of MSCs significantly increased the corneal
thickness and transparency and lowered light scattering in
keratocyte-dysfunctional mice by their similar phenotype
with keratocytes and expression of keratocyte-unique
keratan-sulfated keratocan and lumican after transplant-
ation [39]. Recently, Agorogiannis et al. report a case
using 3 × 106 autologous MSCs topically applied to the
bottom of a corneal ulcer for a persistent sterile corneal
epithelial defect [40]. The corneal stroma is connective
tissue maintained by keratocytes, which are quiescent
mesenchymal cells of neural crest origin [41], and the
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the same. It is speculated that the stroma serves as a niche
for long-term OFSC engraftment. In addition, topical ad-
ministration of OFSCs to the cornea with an epithelial de-
fect provides a diffuse distribution of OFSCs in the
stroma, and which favors direct OFSC-keratocyte interac-
tions in comparison with an intrastromal injection. Future
studies on developing bioactive stem cell eye drops are on-
going in our lab.
Conclusions
Topical administration of allogenic OFSCs is a simple,
non-invasive method of delivering stem cells for corneal
tissue regeneration. Inflammatory inhibition and corneal
epithelial differentiation by OFSCs are responsible for
corneal wound healing in the first few days, and corneal
stroma engraftment of OFSCs at a late stage is associ-
ated with corneal transparency.
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